PCRX:NASDAQPacira BioSciences, Inc. Analysis

Pacira BioSciences (PCRX) trades at $22.99, sitting below its 20‑day SMA of 23.07 and the 50‑day SMA of 23.64, suggesting a modest downside bias. The 14‑day RSI at 47 points to a neutral momentum, while the MACD line has turned bullish with a positive histogram, indicating potential short‑term upside. Volatility is elevated at ~33% over the past 30 days, but the beta of 0.44 signals lower systematic risk than the market. The stock’s trailing PE of 177 dwarfs the industry average of 25, yet the forward PE of 6.3 and a DCF‑derived fair value of $35.80 imply a 29% upside from current levels. Recent Q1 2026 results showed a 5% year‑over‑year revenue increase to $177.4 M, and updated three‑year data on the PCRX‑201 gene‑therapy platform demonstrated sustained efficacy for up to 156 weeks.
Analyst consensus remains a “Buy” with a median price target of $28.5, and a notable endorsement from Renaissance Technologies, which expects a >20% rally. The balance sheet holds $202 M in cash against $411 M of debt, yielding a debt‑to‑equity of ~63%; however, operating cash flow remains positive, supporting ongoing R&D. With a low dividend yield (none) and a modest ROE of 0.7%, the valuation leans toward undervalued relative to its growth prospects. Overall, the combination of technical bullish signals, meaningful pipeline milestones, and a sizable DCF upside supports a positive outlook across horizons.